甲泼尼龙静脉注射辅助对症干预治疗重症高龄CAP疗效及安全性探讨

发布时间：2018-05-14 15:36

本文选题：甲泼尼龙 + 重症　；参考：《中国地方病防治杂志》2016年08期

【摘要】：目的探讨甲泼尼龙静脉注射辅助对症干预治疗重症高龄CAP临床疗效及安全性。方法研究对象选取我院2013年4月-2016年4月收治重症高龄CAP患者共200例,以随机区组法分为对照组(100例)和观察组(100例),分别采用常规对症干预治疗和在此基础上加用甲泼尼龙静脉注射辅助治疗;比较两组患者近期疗效,呼吸道症状体征消失时间,WBC计数恢复正常时间,住院时间,治疗前后CRP水平,二次感染率、死亡率及不良反应发生率等。结果观察组患者近期疗效显著优于对照组,差异有显著性意义(P0.05);观察组患者呼吸道症状体征消失时间和住院时间均显著短于对照组,差异有显著性意义(P0.05);观察组患者治疗后CRP水平显著低于对照组和治疗前,差异有显著性意义(P0.05);观察组患者二次感染率和死亡率均显著低于对照组,差异有显著性意义(P0.05);同时两组患者不良反应发生率比较差异无显著性意义(P0.05)。结论甲泼尼龙静脉注射辅助对症干预治疗重症高龄CAP可有效缩短临床病程,控制炎症反应水平,降低二次感染和死亡风险,且未增加不良反应发生几率。
[Abstract]:Objective to investigate the clinical efficacy and safety of methylprednisolone intravenous intervention in the treatment of advanced age CAP. Methods from April 2013 to April 2016, 200 elderly CAP patients were treated in our hospital. The control group (n = 100) and the observation group (n = 100) were divided into control group (n = 100) and observation group (n = 100). The time of disappearance of respiratory symptoms and signs, the time of return to normal, the time of hospitalization, the level of CRP before and after treatment, the secondary infection rate, the mortality rate and the incidence of adverse reactions. Results the short-term curative effect of the observation group was significantly better than that of the control group (P 0.05), the time of disappearance of respiratory symptoms and signs and the hospitalization time of the observation group were significantly shorter than those of the control group. The levels of CRP in the observation group were significantly lower than those in the control group and before treatment, and the secondary infection rate and mortality rate in the observation group were significantly lower than those in the control group. At the same time, there was no significant difference in the incidence of adverse reactions between the two groups. Conclusion methylprednisolone intravenous injection can effectively shorten the clinical course of CAP, control the level of inflammatory reaction, reduce the risk of secondary infection and death, and do not increase the incidence of adverse reactions.
【作者单位】：钦州市中医医院肺病科;钦州市中医医院脾胃科;
【分类号】：R563.1

【相似文献】